|
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria |
Jun 2024 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Kidney involvement in myelodysplastic syndromes |
Jun 2024 |
Clinical Kidney Journal |
Myelodysplastic Syndromes (MDS) |
|
Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition |
Jun 2024 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Acquired Aplastic Anemia Therapies: Immunosuppressive Therapy Versus Alternative Donor Hematopoietic Cell Transplantation |
Jun 2024 |
Journal of Hematology |
Aplastic Anemia |
|
Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria |
Jun 2024 |
Blood Advances |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria. Reply |
Jun 2024 |
The New England Journal of Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria |
Jun 2024 |
The New England Journal of Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria |
Jun 2024 |
The New England Journal of Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Iptacopan and danicopan for paroxysmal nocturnal hemoglobinuria |
Jun 2024 |
Journal of Managed Care & Specialty Pharmacy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Granulocyte transfusions in severe aplastic anemia |
Jun 2024 |
Haematologica |
Aplastic Anemia |
